Onconova Advances Oral Rigosertib to Phase II Clinical Trial in ... 
MarketWatch (press release)
The intravenous (IV) formulation of rigosertib is currently in a pivotal Phase III trial for refractory myelodysplastic syndromes (MDS) in the US and EU. "A randomized Phase II evaluation of oral rigosertib will be conducted in patients with Low or ...

and more » 

Onconova Advances Oral Rigosertib to Phase II Clinical Trial in ... 
EON: Enhanced Online News (press release)
The intravenous (IV) formulation of rigosertib is currently in a pivotal Phase III trial for refractory myelodysplastic syndromes (MDS) in the US and EU. ?A randomized Phase II evaluation of oral rigosertib will be conducted in patients with Low or ...

and more » 

UK Announces $6.25 Million Cancer Research Grant 
LEX18 Lexington KY News
A $5 million grant from the Edward P. Evans Foundation, along with a $1.25 million donor gift, will fund research of myelodysplastic syndrome (MDS). The Evans Foundation grant will fund five research labs over five years, including three labs at UK, ...
UK receives $6.25 million research grant, gift for post-cancer ailment Lexington Herald Leader

all 34 news articles » 

Markey receives $6.25 million to study deadly cancer 
The Lane Report
A $5 million grant from the Edward P. Evans Foundation, along with a $1.25 million donor gift, will fund research of myelodysplastic syndrome (MDS). The Evans Foundation grant will fund five research labs over five years, including three labs at UK, ...
UK center receives $6M to study deadly disease The Courier-Journal
Markey Cancer Center receives $6.25 million for research Kykernel.com (subscription)

all 7 news articles » 

Alan McKelvey Bentley 
Jamestown Post Journal
Alan McKelvey Bentley, 80, passed away peacefully on Saturday morning, May 5, 2012, after a three-month battle with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome, in Northside Hospital in Cumming, Ga. Passing on Cinco de Mayo is ironic as ...

 

Cyclacel Announces Completion of Enrollment in Investigator-Initiated, Phase 2 ... 
MarketWatch (press release)
... to low dose cytarabine (the "Pick a Winner Programme / LI-1 Trial") in patients aged 60 years or older with previously untreated acute myeloid leukemia (AML) or high risk myelodysplastic syndromes (MDS) who are unfit for intensive chemotherapy.
Cyclacel Reports First Quarter 2012 Financial Results Broadcast Newsroom

all 11 news articles » 

Thalidomide-Trisenox Combination May Be Effective And Safe In MDS Patients 
The MDS Beacon
Both Thalidomide (Thalomid) and Trisenox (arsenic trioxide) have been previously investigated as potential treatments for myelodysplastic syndromes (MDS). Thalidomide, which is closely related to Revlimid (lenalidomide), has effectively been used in ...

 

Cyclacel to Report New Sapacitabine Clinical Data at the American Society of ... 
MarketWatch (press release)
Sapacitabine oral capsules is in the SEAMLESS Phase 3 trial being conducted under an SPA with the FDA as front-line treatment of acute myeloid leukemia (AML) in the elderly, Phase 2 studies for AML, myelodysplastic syndromes (MDS), solid tumors ...

and more » 

Retired Staten Island firefighter meets donor who helped save his life 
SILive.com
Wallen, 48, suffered from myelodysplastic syndrome, which decimated his bone marrow and blood. He received a stem cell transplant in 2005 from his closest bone marrow match in the world, Florian Beber of Lake Constance, Germany.

 

Stem Cell Transplantation In Elderly MDS Patients: The Role Of Treatment ... 
The MDS Beacon
Donor, or allogeneic, stem cell transplantation is currently the only treatment available that may cure patients with myelodysplastic syndromes (MDS). In this procedure, MDS patients receive stem cells from a healthy donor to replenish their own stem ...